Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, United States.
Department of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Front Immunol. 2021 Jun 25;12:704072. doi: 10.3389/fimmu.2021.704072. eCollection 2021.
Complement impacts innate and adaptive immunity. Using a model in which the human KEL glycoprotein is expressed on murine red blood cells (RBCs), we have shown that polyclonal immunoprophylaxis (KELIg) prevents alloimmunization to transfused RBCs when a recipient is in their baseline state of heath but with immunoprophylaxis failure occurring in the presence of a viral-like stimulus. As complement can be detected on antibody coated KEL RBCs following transfusion, we hypothesized that recipient complement synergizes with viral-like inflammation to reduce immunoprophylaxis efficacy. Indeed, we found recipient C3 and C1q were critical to immunoprophylaxis failure in the setting of a viral-like stimulus, with no anti-KEL IgG alloantibodies generated in C3 or C1q mice following KELIg treatment and KEL RBC transfusion. Differences in RBC uptake were noted in mice lacking C3, with lower consumption by splenic and peripheral blood inflammatory monocytes. Finally, no alloantibodies were detected in the setting of a viral-like stimulus following KELIg treatment and KEL RBC transfusion in mice lacking complement receptors (CR1/2), narrowing key cells for immunoprophylaxis failure to those expressing these complement receptors. studies showed complement fixed opsonized RBCs were significantly less likely to bind to B-cells from CR1/2 than wild type mice, potentially implicating lowered B-cell activation threshold in the presence of complement as being responsible for these findings. We thus propose a two-hit model for inflammation-induced immunoprophylaxis failure, where the first "hit" is recipient inflammation and the second "hit" is complement production/sensing. These results may have translational relevance to antigen-antibody interactions in humans.
补体影响固有和适应性免疫。我们使用在鼠红细胞(RBC)上表达人 KEL 糖蛋白的模型表明,多克隆免疫预防(KELIg)可防止受体在基线健康状态下对输注 RBC 产生同种免疫,但在存在病毒样刺激时会发生免疫预防失败。由于补体可在输注后在抗体包被的 KEL RBC 上检测到,因此我们假设受体补体与病毒样炎症协同作用以降低免疫预防效果。事实上,我们发现,在病毒样刺激的情况下,受体 C3 和 C1q 对免疫预防失败至关重要,在 C3 或 C1q 缺乏的小鼠中,在接受 KELIg 治疗和 KEL RBC 输注后未产生抗-KEL IgG 同种抗体。在缺乏 C3 的小鼠中注意到 RBC 摄取存在差异,脾和外周血炎症性单核细胞的消耗减少。最后,在缺乏补体受体(CR1/2)的情况下,在接受 KELIg 治疗和 KEL RBC 输注后,在病毒样刺激下未检测到同种抗体,从而将免疫预防失败的关键细胞缩小为表达这些补体受体的细胞。研究表明,固定补体的致敏 RBC 与 CR1/2 缺乏的小鼠相比,与 B 细胞的结合明显减少,这可能表明在补体存在下降低了 B 细胞激活阈值,这是造成这些发现的原因。因此,我们提出了一种炎症诱导免疫预防失败的双打击模型,其中第一个“打击”是受体炎症,第二个“打击”是补体的产生/感应。这些结果可能对人类的抗原-抗体相互作用具有转化意义。